Could EMERALD-3 redefine the treatment paradigm for unresectable hepatocellular carcinoma?

In this special roundtable discussion recorded at ASCO 2026, Dr. Ghassan Abou-Alfa is joined by Dr. Gentry King, Dr. Mehmet Akce, Dr. Pierre Gholam, Dr. Lingling Du, Dr. Adam Burgoyne, Dr. Lipika Goyal, and Dr. Riad Salem to break down the landmark EMERALD-3 study.

The panel explores the scientific rationale for combining transarterial chemoembolization (TACE) with immunotherapy and antiangiogenic therapy, while reviewing key efficacy findings from the EMERALD-3 study. Beyond the data, the experts discuss how locoregional therapies can enhance immune responses, and examine the practical challenges of patient selection, multidisciplinary decision-making, treatment sequencing, and the evolving role of interventional radiology in modern HCC management.

Topics discussed include:

• EMERALD-3 trial design and results
• TACE plus systemic therapy in HCC
• Durvalumab and immunotherapy strategies
• Lenvatinib and antiangiogenic therapy
• Synergy between embolization and immunotherapy
• Locoregional therapy in unresectable HCC
• Progression-free survival and clinical outcomes
• Multidisciplinary management of liver cancer
• Interventional radiology and oncology collaboration
• Patient selection for combination therapy
• Future directions in hepatocellular carcinoma treatment
• How EMERALD-3 may influence clinical practice

As treatment options continue to expand, understanding how systemic therapy and locoregional interventions work together may be key to improving outcomes for patients with liver cancer.

Subscribe for more expert oncology discussions, clinical trial updates, and insights from leading cancer specialists.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

How are we navigating the evolving landscape of second-line treatment for metastatic HR-positive, HER2-negative breast cancer?

In this full-length discussion, Dr. Ursa Brown-Glaberman and Dr. Karthik Giridhar explore one of the most rapidly evolving areas in breast oncology: treatment selection after progression on first-line endocrine therapy and CDK4/6 inhibitors.

The conversation examines how molecular profiling, ctDNA testing, AKT pathway targeting,PIK3CA alterations, ESR1 mutations, and emerging biomarkers are reshaping decision-making in the second-line setting. The experts also discuss how they approach endocrine therapy sequencing, when to transition to ADCs, and how toxicity, quality of life, and patient preferences influence treatment selection.

Topics discussed include:

• Second-line treatment strategies in HR-positive metastatic breast cancer
• Endocrine therapy sequencing after CDK4/6 inhibitors
• ESR1 mutation testing and ctDNA monitoring
• Tissue biopsy versus liquid biopsy
• PIK3CA mutations and targeted therapies
• Capivasertib versus alpelisib decision-making
• AKT pathway inhibition in metastatic disease
• Germline BRCA and PALB2 testing
• Biomarker-driven treatment selection
• When to transition from endocrine therapy to ADCs
• Quality of life considerations in metastatic breast cancer
• The future of personalized treatment sequencing

As the treatment landscape continues to expand, understanding how to personalize second-line therapy has become one of the most important challenges in modern breast cancer care.

Subscribe for more expert oncology discussions, breast cancer treatment updates, and clinical insights from leading specialists.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

How is trastuzumab deruxtecan (T-DXd) reshaping treatment across early-stage and metastatic HER2-positive breast cancer?

Dr. Sarah Premji, Dr. Reshma Mahtani, and Dr. Eleftherios "Terry" Mamounas discuss the practice-changing implications of DESTINY-Breast11, DESTINY-Breast05, and DESTINY-Breast09, exploring how T-DXd is moving earlier in the treatment paradigm and influencing decision-making from the neoadjuvant setting through first-line metastatic disease.

The conversation examines pathologic complete response (pCR), residual disease management, toxicity monitoring, multidisciplinary care, and the evolving role of biomarkers in treatment personalization.

Topics include:

• DESTINY-Breast11 and neoadjuvant T-DXd strategies
• Pathologic complete response (pCR) and treatment de-escalation
• Residual disease management after neoadjuvant therapy
• DESTINY-Breast05 and adjuvant T-DXd in high-risk disease
• Monitoring and managing interstitial lung disease (ILD)
• Patient education, supportive care, and toxicity mitigation
• Multidisciplinary collaboration in HER2-positive breast cancer care
• DESTINY-Breast09 and first-line metastatic treatment advances
• T-DXd plus pertuzumab in metastatic HER2-positive disease
• Future roles for ctDNA and biomarker-guided treatment decisions

As HER2-directed therapies continue to evolve, clinicians are increasingly challenged to determine when to introduce the most effective treatments, how to manage long-term toxicities, and how to personalize care across the entire disease continuum.

Watch more expert oncology discussions from Community Health Media and subscribe for future conversations with leading oncology experts.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

Can T-DXd plus pertuzumab finally replace the CLEOPATRA regimen as the new first-line standard for metastatic HER2-positive breast cancer?

In this comprehensive discussion from ASCO 2026, Dr. Jason Mouabbi, Dr. Fengting Yan, and Dr. Paolo Tarantino break down the practice-changing DESTINY-Breast09 data and what it means for treatment sequencing, patient selection and toxicity management. Beyond the clinical trial results, the experts share their perspectives on the evolving therapeutic landscape—specifically, the future possibility of achieving cures in metastatic HER2-positive breast cancer.

The panel explores why antibody-drug conjugates are moving earlier in treatment, the impressive progression-free survival results from DESTINY-Breast09, the significance of deep partial responses, and how clinicians should think about treatment duration, maintenance strategies, and long-term disease control.

Topics discussed include:

• DESTINY-Breast09 study design and results
• T-DXd plus pertuzumab vs CLEOPATRA (THP)
• Progression-free survival and response outcomes
• Deep partial response vs complete response
• Attrition rates and why first-line therapy matters
• ILD monitoring and management strategies
• Nausea, fatigue, and alopecia management
• Olanzapine for T-DXd-associated nausea
• PIK3CA-mutated HER2-positive disease
• PATINA and HER2CLIMB-05 implications
• Maintenance therapy considerations
• Rechallenging T-DXd after recurrence
• ADC sequencing in metastatic HER2-positive breast cancer
• The possibility of cure in metastatic HER2-positive disease

As treatment options continue to evolve, understanding how to maximize the benefits of T-DXd while managing toxicity will be critical for improving outcomes in HER2-positive metastatic breast cancer.

Subscribe for more expert oncology discussions, breast cancer treatment updates, and ASCO 2026 coverage.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

How is T-DXd reshaping treatment for patients with early-stage HER2-positive breast cancer

Dr. Abi Siva and Dr. Carey Anders discuss the evolving role of T-DXd across the treatment continuum, including the latest data from DESTINY-Breast11 and DESTINY-Breast05. The conversation explores how these studies are influencing neoadjuvant and adjuvant treatment strategies, patient selection, toxicity management, and future sequencing decisions.

The experts examine key clinical questions surrounding pCR, residual disease management, ILD monitoring, radiation considerations, treatment duration, recurrence after T-DXd exposure, and how clinicians may approach increasingly complex treatment decisions as T-DXd moves into earlier-stage disease.

Topics discussed include:

• DESTINY-Breast11 and neoadjuvant T-DXd
• DESTINY-Breast05 and residual disease management

• Pathologic complete response (pCR) outcomes
• T-DXd versus T-DM1 in the adjuvant setting
• Patient selection for neoadjuvant therapy
• ILD monitoring and management strategies
• Radiation pneumonitis versus drug-related ILD
• Treatment duration considerations
• ctDNA and future biomarker strategies
• CNS recurrence considerations
• Recurrence after prior T-DXd exposure
• Sequencing therapies in HER2-positive breast cancer
• Community versus academic practice considerations
• Future directions in HER2-positive disease

As T-DXd continues to move earlier in treatment, clinicians must balance maximizing efficacy with minimizing toxicity. This discussion highlights the practical considerations that may shape the future standard of care for HER2-positive breast cancer.

Subscribe for more expert oncology discussions, breast cancer treatment updates, and clinical insights from leading specialists.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

Metastatic triple-negative breast cancer has long been one of the most challenging breast cancer subtypes to treat. But with the emergence of ADCs, the treatment landscape is rapidly evolving.

In this in-depth discussion from ASCO 2026, Dr. Megan Kruse, Dr. Ryan Rader, and Dr. Praveen Vikas explore the latest advances in first-line treatment for metastatic TNBC, including the recently approved datopotamab deruxtecan and the growing role of sacituzumab govitecan.

The panel reviews key findings from the TROPION-Breast02 and ASCENT-03 trials, discusses overall survival and progression-free survival outcomes, compares toxicity profiles, and shares practical guidance on selecting between ADC options in real-world clinical practice.

Topics discussed include:

• TROPION-Breast02 and Dato-DXd approval
• ASCENT-03 and sacituzumab govitecan data
• First-line treatment selection in metastatic TNBC
• PD-L1 positive vs PD-L1 negative disease
• ADC sequencing challenges
• Managing ocular toxicity, stomatitis, and ILD
• Quality-of-life considerations
• Germline BRCA testing and PARP inhibitors
• Patient-centered treatment decision-making
• Future directions in metastatic triple-negative breast cancer

As treatment options continue to expand, clinicians face increasingly complex decisions about sequencing, toxicity management, and delivering the most effective therapy early in the disease course.

Subscribe for more expert oncology discussions, ASCO 2026 highlights, and breast cancer treatment updates.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

How should clinicians integrate T-DXd across the entire HER2-positive breast cancer treatment continuum?

Dr. Megan Kruse, Dr. William Gradishar, and Dr. Ajaz Khan discuss the evolving role of trastuzumab deruxtecan (T-DXd) in early-stage and metastatic HER2-positive breast cancer. From DESTINY-Breast11 and DESTINY-Breast05 to first-line metastatic DESTINY-Breast09 strategies, the conversation explores how recent data are reshaping treatment decisions, patient selection, toxicity management, and long-term sequencing approaches.

Topics discussed include:

• DESTINY-Breast11 and neoadjuvant T-DXd
• DESTINY-Breast05 and residual disease management
• Pathologic complete response (pCR) outcomes
• Selecting patients for neoadjuvant vs adjuvant T-DXd
• ILD monitoring and toxicity management
• T-DXd sequencing after recurrence
• First-line metastatic treatment strategies
• DESTINY-Breast09 implications
• T-DXd plus pertuzumab in metastatic disease
• Quality of life and long-term treatment planning
• ctDNA, treatment duration, and future research directions

As T-DXd expands across earlier and later stages of HER2-positive breast cancer, clinicians face new opportunities and new questions about how best to maximize outcomes while minimizing toxicity.

Subscribe to Community Health Media for more expert oncology discussions, clinical insights, and updates from the latest advances in cancer care.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

How should clinicians approach endocrine resistance in ER-positive metastatic breast cancer?

Dr. Mark Pegram and Dr. Seth Wander explore the evolving science of endocrine resistance, ESR1 mutations, liquid biopsy testing, and precision oncology in hormone receptor-positive, HER2-negative metastatic breast cancer. Drawing from decades of research and clinical experience, they discuss how resistance develops, why repeat molecular testing matters, and how emerging therapies are reshaping treatment strategies.

The conversation covers:

• Mechanisms of endocrine resistance in metastatic breast cancer
• ESR1 mutations and their clinical significance
• Aromatase inhibitor resistance and tumor evolution
• Liquid biopsy versus tissue biopsy for mutation detection
• When to test for ESR1 mutations in clinical practice
• PADA-1 and the emergence of mutation-guided treatment strategies
• The SERENA-6 trial and early intervention with camizestrant
• ctDNA monitoring and precision medicine approaches
• Quality-of-life outcomes and patient-reported benefits
• Challenges interpreting PFS, PFS2, and overall survival data
• The ODAC review of SERENA-6
• Future directions for oral SERDs and ESR1-targeted therapies
• The promise of personalized treatment for endocrine-resistant disease

This in-depth discussion examines one of the most important emerging areas in breast oncology and what it may mean for the future of precision medicine in metastatic breast cancer. Based on transcript content.

Subscribe to Community Health Media for more expert discussions on breast cancer, precision oncology, and emerging clinical research.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

TNBC has long been one of the most difficult breast cancer subtypes to treat. But with ADCs reshaping the treatment landscape, are we finally entering a new era for metastatic TNBC?

In this in-depth discussion, Dr. Jason Mouabbi, Dr. Alison Conlin, and Dr. Reva Basho explore the rapidly evolving first-line treatment landscape for metastatic triple-negative breast cancer, with a particular focus on patients who are PD-L1 negative or otherwise ineligible for immunotherapy.

The panel reviews the landmark TROPION-Breast02 and ASCENT-03 trials, examining how Dato-DXd and sacituzumab govitecan are challenging decades of chemotherapy-based standards. They discuss overall survival and progression-free survival outcomes, ADC toxicity management, patient selection, treatment sequencing, crossover effects in clinical trials, quality-of-life considerations, and the growing role of personalized treatment decisions.

The conversation also addresses one of the most pressing realities in TNBC care: many patients never reach second-line therapy, making first-line treatment selection more important than ever. From clinical trial design to real-world implementation, the experts provide practical insights into how these new therapies are changing patient outcomes today.

Topics discussed include:

• First-line treatment strategies in metastatic TNBC
• PD-L1-negative and immunotherapy-ineligible disease
• TROPION-Breast02 trial results
• ASCENT-03 trial findings
• Dato-DXd vs sacituzumab govitecan
• ADC efficacy and overall survival outcomes
• Toxicity management and patient quality of life
• ADC sequencing strategies
• Chemotherapy versus ADCs
• Clinical trial design and crossover considerations
• Patient selection and shared decision-making
• Future directions in metastatic breast cancer

Subscribe for more expert oncology discussions, breast cancer treatment updates, and clinical insights from leading specialists.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠

How will DESTINY-Breast11 and DESTINY-Breast05 change the treatment of early-stage HER2-positive breast cancer?

Dr. Gregory Vidal, Dr. Pooja Advani, and Dr. Tari King discuss the landmark approvals of trastuzumab deruxtecan (T-DXd) and what they mean for medical oncologists and surgeons treating HER2-positive breast cancer. The conversation explores the impressive pathologic complete response rates seen in DESTINY-Breast11, the role of T-DXd in the neoadjuvant and adjuvant settings, surgical implications of higher response rates, and how clinicians can personalize treatment decisions for high-risk patients.

Topics include:

• DESTINY-Breast11 and DESTINY-Breast05 overview
• T-DXd in the neoadjuvant setting
• Pathologic complete response (pCR) outcomes
• Hormone receptor-positive HER2-positive disease
• Residual Cancer Burden (RCB) and prognosis
• Adjuvant treatment strategies after surgery
• De-escalation of axillary surgery
• Breast conservation opportunities
• Multidisciplinary treatment planning
• Patient selection and implementation in clinical practice
• The evolving role of surgeons in treatment sequencing
• Future directions in HER2-positive breast cancer

This comprehensive discussion examines how T-DXd is reshaping the treatment landscape of early-stage HER2-positive breast cancer and highlights the importance of collaboration between medical oncology and surgical oncology teams.

Subscribe to Community Health Media for more expert oncology discussions, clinical insights, and updates from the latest cancer research.

–Thanks for watching!Our podcasts are also available on:

• Spotify - ⁠https://spotf.fi/chm-podcast⁠
• Amazon Music - ⁠https://amazn.so/chm-podcast⁠
• Apple Podcast - ⁠https://podcasts.apple.com/us/podcast...⁠
• Castbox - ⁠https://castbox.fm/vh/6735434⁠
• Goodpods - ⁠https://goodpods.com/profile/chm-111066⁠
• iHeartRadio - ⁠https://iheart.com/podcast/291542082⁠
• Pocket Casts - ⁠https://pca.st/3ncdh11o⁠

–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in:

• Peer to peer interviews, panels & round-tables
• Curated live events & conferences
• Professional in-depth content & research updates
• Interactive learning modules & webinars
• Live & on-demand webcasts & podcasts

Learn more about us here - ⁠https://communityhealth.media⁠